Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Khosla Ventures
Biotech
Stylus outlines next-gen gene editing mission with $85M in hand
The 40-person company is led by CEO Emile Nuwaysir, Ph.D., former CEO of Bayer’s cell therapy outfit BlueRock Therapeutics.
Gabrielle Masson
May 13, 2025 7:00am
Merck bets up to $1B on Pearl's 'smart' biologics
Mar 12, 2024 8:00am
Valo blames 'market conditions' for end of $750M Khosla deal
Nov 17, 2021 9:05am
Valo to go public via Khosla-backed SPAC, gaining $500M-plus
Jun 10, 2021 4:11am
Synchron pockets $40M for thought-controlled paralysis tech
Jun 4, 2021 10:55am
GI AI developer Docbot nets new CEO, series A funding
May 24, 2021 11:24am
